Arch Neurol Chicago
-
Arch Neurol Chicago · Oct 2002
Randomized Controlled Trial Multicenter Study Clinical TrialEffects of coenzyme Q10 in early Parkinson disease: evidence of slowing of the functional decline.
Parkinson disease (PD) is a degenerative neurological disorder for which no treatment has been shown to slow the progression. ⋯ Coenzyme Q10 was safe and well tolerated at dosages of up to 1200 mg/d. Less disability developed in subjects assigned to coenzyme Q10 than in those assigned to placebo, and the benefit was greatest in subjects receiving the highest dosage. Coenzyme Q10 appears to slow the progressive deterioration of function in PD, but these results need to be confirmed in a larger study.